In the News

1855 News Items found
Charles Rudin with lab member
During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).
Dr. Jun Mao with patient
During the upcoming ASCO Virtual Scientific Program, MSK Chief of Integrative Medicine, Jun J. Mao, MD, MSCE will be presenting a new study comparing the effectiveness of electro-acupuncture (EA) and auricular acupuncture (AA) versus usual care (UC) for chronic musculoskeletal pain in cancer survivors.
Nitya Raj
Learn the keys to a successful telemedicine visit from a cancer specialist at Memorial Sloan Kettering.
ASCO20 Virtual Scientific Program
Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program. MSK physicians and scientists are involved in notable research to be presented at the meeting.
X and Y chromosomes in mice
In the Lab
One’s big, one’s small. Somehow, they make it work.
Jeffrey Drebin, MD, PhD
Concerns around COVID-19 are common in the general population, but cancer patients are also balancing questions about what the pandemic means for their treatment, prognosis, and vulnerability to the virus.
Two gloved hands opening a drawer in a laboratory.
Feature
Discovery reveals that the genetic causes of cancer may be more complicated than previously thought.
A fluorescent image of cells undergoing differentiation in a mouse model.
In Brief
The discovery links metabolism to the way cancer stem cells form tumors.
Alexander Drilon, MD
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to selpercatinib (Retevmo™) for lung and thyroid cancers with RET (REarranged during Transfection) gene mutations or fusions.
Katherine High, MD
The May 20 installment of “MSK Science Spotlight” will feature guest speaker, Katherine High, MD, Professor Emerita, Perelman School of Medicine of the University of Pennsylvania; Co-founder and former President and Head of R&D, Spark Therapeutics.